In its first Super Bowl ad, HR and IT platform Rippling taps comedian Tim Robinson to dramatize how fragmented software can derail business ambitions, launching a new brand campaign aimed at mainstream audiences.
The Panama Canal Authority has unveiled stringent pre-qualification criteria for firms bidding on two major new terminals, demanding proven global scale and experience, as it advances an $8.5 billion modernization plan amid recent port contract upheavals.
Despite a recent 4.6% bounce, Ethereum faces mounting headwinds as key metrics tracking long-term holder conviction have plummeted nearly 90%, raising the specter of a deeper correction toward $1,500.
Amid a tech-led market rally, Diamond Hill Capital's Large Cap Fund took a contrarian position in the fourth quarter, initiating a stake in natural gas producer EQT Corporation. The fund's latest letter outlines a cautious view on AI euphoria while positioning for resilience in energy fundamentals.
Diamond Hill Capital's latest investor letter highlights General Motors' resilient performance in Q4 2025, even as the fund expresses caution toward AI-driven market euphoria and lags behind the broader value index.
China's COMAC showcases its C919 narrowbody jet at the Singapore Airshow, aiming to boost international sales after strong domestic adoption but facing geopolitical and market barriers abroad.
The Marzetti Company reported fourth-quarter revenue in line with Wall Street expectations at $518 million, though earnings per share fell short. While its foodservice segment saw growth, retail sales softened, highlighting ongoing challenges for the specialty food maker.
Gold and silver prices rebounded sharply in European trading Tuesday, recovering from a two-day plunge as fundamental demand drivers and attractive levels lured buyers back to the market.
A reader asks if taxes can be completely avoided when converting a 401(k) to a Roth IRA. While a full escape isn't possible, financial experts outline key timing and planning strategies to significantly reduce the long-term tax burden.
Citi Research has initiated coverage on Sanofi with a Neutral rating and an €85 price target, citing pipeline setbacks and a lack of near-term catalysts. The analysis comes as the French pharma giant reports positive Phase 3 results for its eczema drug amlitelimab.
Goldman Sachs raises its price target for Energy Transfer LP (ET) to $19, citing the upcoming USAC/J-W Power deal and adjustments in NGL and crude oil segment forecasts, while maintaining a Neutral rating amid near-term EBITDA headwinds.
Keurig Dr Pepper has launched an $18 billion all-cash offer to acquire Dutch coffee giant JDE Peet's, a move set to reshape the global beverage landscape and split KDP into two separate public companies.
Elon Musk consolidates his space and AI ventures as SpaceX acquires xAI, with a combined valuation nearing $1.25 trillion. The move precedes a highly anticipated SpaceX IPO that could become the largest in history and reignite the global market for new listings.
Mizuho Securities lowered its price target for Qualcomm, citing a weaker outlook for global smartphone shipments and increased competition. The firm projects a potential decline in handset production and pressures from rising memory costs.
Specialty materials maker ATI (NYSE: ATI) saw its shares surge after reporting fourth-quarter earnings that topped estimates, even as revenue came in slightly below Wall Street forecasts. The company pointed to strong demand in aerospace and defense as a key driver.
Electrical equipment maker Hubbell (NYSE:HUBB) reported fourth-quarter sales of $1.49 billion, aligning with Wall Street estimates, though underlying organic growth signals a moderation in demand.
In a strategic move to bridge traditional finance and digital assets, Deutsche Börse Group's 360T has partnered with Austrian crypto platform Bitpanda. The collaboration leverages Europe's new MiCA framework to offer institutional clients a compliant gateway into cryptocurrency trading and retail services.
Industrial electronics giant AMETEK (NYSE:AME) delivered a strong top-line performance for the fourth quarter of 2025, surpassing revenue expectations with 13.4% year-over-year growth. However, a closer look reveals pressure on operating margins, painting a nuanced picture for the diversified manufacturer.
Following a modest 2.8% increase this year, early projections from the Senior Citizens League suggest next year's Social Security cost-of-living adjustment could shrink to 2.5%, intensifying concerns over retirees' eroding purchasing power amid rising healthcare costs.
Merck & Co. reported solid fourth-quarter revenue growth driven by its blockbuster cancer drug Keytruda, but the pharmaceutical giant forecasts a slowdown in earnings growth as it absorbs billions in costs from recent acquisitions aimed at diversifying its pipeline ahead of Keytruda's patent expiration.
